sotagliflozin
Ligand Summary
Sotagliflozin is a dual inhibitor of sodium glucose cotransporter type 1 (SGLT1) and SGLT2. Local intestinal inhibition of SGLT1, the major transporter for glucose absorption, delays and reduces glucose absorption in the proximal intestine, resulting in a blunting and delay of postprandial hyperglycaemia. SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, sotagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion
PubChem: 24831714
Guide to Pharmacology: 8312
ChEMBL: CHEMBL3039507
DrugCentral: 5339
LyCHI: 2D3WNDRLVSWV
Target Activities
16 Activities
Items per page:
10
1 – 10 of 16
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||